HealthyDirect · GrowthFit for a long SIP
HDFC Pharma and Healthcare Fund
HDFC Mutual FundEquity Scheme - Sectoral/ Thematic3.1 years
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
- NAV
- 21.496
- 27 Oct 2026
- 1Y
- +18.7%
- Trailing CAGR
- AUM
- ₹3,501.37 Cr
- 30 Sept 2026
- Volatility
- Medium
- 14.1% annualized
Buying brief
Should you add this fund?
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 26 Oct 2026
Stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
In three lines
Fits if · The fund beat the category median in 100% of rolling 3-year windows.
Fits if · Three-year return is above the category median.
Buy checklist
History depth
Watch
3.1 years - usable, still building a track record.
Engine status
Pass
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Expense ratio
Pass
1.05% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -14.9%. Ask whether you can hold through a similar fall.
Vs category
Pass
100% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
Pass
Dhruv Muchhal · 3.1 years on the scheme.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 49.2% of the portfolio.
Evidence supports a shortlist - confirm with peers before you buy elsewhere.
Before you buy or SIP
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 15%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
Path not in current snapshots
n/a
Returns
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
- 1Y+18.7%
- 3Y+29.3%
- 5Yn/a
- 10Yn/a
- SI+27.7%
SIP XIRR
Equal monthly instalments to latest NAV
- 1Y+18.3%
- 3Y+20.5%
- 5Yn/a
- 10Yn/a
- Since inception
- +27.7%
- Calendar-day CAGR
- Excess 1Y
- +23.8%
- Category median, same plan and option
- 3Y win rate
- +100%
- Windows beating the median
- 3Y percentile
- 98
- Vs comparable share classes
- SIP 3Y XIRR
- +20.5%
- Simulated monthly SIP
- Worst rolling 3Y
- +27.7%
- 15 daily-ending windows
- Median rolling 3Y
- +28.9%
- Calendar-day CAGR
- Positive rolling 5Y
- n/a
- 0 daily-ending windows
Drawdown
Peak to trough from a running NAV high, with the path and recovery episodes.
- Max drawdown
- -14.9%
- Worst peak-to-trough
- Current
- -8.1%
- Below last peak
- Current spell
- 35 days
- Days below latest peak
- Time below peak
- +79%
- NAV observations
Drawdown
Path not in current snapshots
n/a
- Average recovery
- 7 days
- 64 recovered episodes
- Longest recovery
- 126 days
- Trough to prior peak
2 Jan 2025 – 4 Jul 2025
Trough 28 Feb 2025 · recovered in 126 days
-14.9%
21 Sept 2026 – open
Trough 23 Oct 2026 · not recovered
-9.8%
30 Jul 2025 – 26 Feb 2026
Trough 2 Feb 2026 · recovered in 24 days
-7.8%
26 Feb 2026 – 22 Apr 2026
Trough 23 Mar 2026 · recovered in 30 days
-6.8%
Dimensions
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
98
Vs category
100
Consistency
98
Risk-adjusted
96
Drawdown
63
Mean
91
Decision
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Healthy
Buying stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Why this status
- No material deterioration, cost shock, or persistent category underperformance in the current evidence set.
Supporting reads
- The fund beat the category median in 100% of rolling 3-year windows.
- Three-year return is above the category median.
- Risk-adjusted return sits above the documented risk-free proxy.
- Peak-to-trough drawdown has stayed shallower than 15%.
Portfolio
30 Sept 2026 · 39 holdings · top 10 are 49.2%.
- Top 5
- 31.1%
- Top 10
- 49.2%
- Largest holding
- 9.4%
- Effective holdings
- 25.0
Divi's Laboratories Ltd
Healthcare
9.4%
Sun Pharmaceutical Industries Ltd
Healthcare
8.3%
Repo
Unspecified
4.7%
Alkem Laboratories Ltd
Healthcare
4.6%
Cipla Ltd
Healthcare
4.2%
Worth investigating
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Sundaram Multi-Factor Fund
Sundaram Mutual Fund
- 1Y
- -10.0%
- 3Y
- n/a
- Vol
- 13.6%
- Max DD
- -14.9%
- Sharpe
- -0.79
- 3Y win
- n/a
- Lower volatility
- Shallower drawdown
Caveat: Higher TER · Lower trailing returns
Kotak Business Cycle Fund
Kotak Mahindra Mutual Fund
- 1Y
- +0.3%
- 3Y
- +15.9%
- Vol
- 12.7%
- Max DD
- -18.4%
- Sharpe
- 0.71
- 3Y win
- +98%
- Lower volatility
- Lower TER
Caveat: Deeper drawdown · Lower trailing returns
Aditya Birla Sun Life Business Cycle Fund
Aditya Birla Sun Life Mutual Fund
- 1Y
- -0.9%
- 3Y
- +12.6%
- Vol
- 13.9%
- Max DD
- -17.8%
- Sharpe
- 0.37
- 3Y win
- +12%
- Lower volatility
Caveat: Deeper drawdown · Higher TER · Lower trailing returns
Baroda BNP Paribas Energy Opportunities Fund
Baroda BNP Paribas Mutual Fund
- 1Y
- -5.9%
- 3Y
- n/a
- Vol
- 13.9%
- Max DD
- -16.1%
- Sharpe
- 0.02
- 3Y win
- n/a
- Lower volatility
Caveat: Deeper drawdown · Higher TER · Lower trailing returns
ICICI PRUDENTIAL HOUSING OPPORTUNITIES FUND
ICICI Prudential Mutual Fund
- 1Y
- -9.2%
- 3Y
- +10.4%
- Vol
- 12.6%
- Max DD
- -16.7%
- Sharpe
- 0.54
- 3Y win
- +66%
- Lower volatility
Caveat: Deeper drawdown · Higher TER · Lower trailing returns